Basilea receives further USD 6 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, February 25, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a ...
Becker's Hospital Review

Majority of Pediatric Beta-Lactamase Producing Infections Are MDR

In a study to identify risk factors and outcomes in extended-spectrum beta-lactamose-producing Enterobacteriaceae infections in pediatric patients, researchers found 77 percent of the infections were ...
Medscape

EMA Backs New Antibiotic for Complex Bacterial Infections

The European Medicines Agency (EMA) has adopted a positive opinion for the marketing authorization of Emblaveo (aztreonam-avibactam), recommended for treating complicated intra-abdominal and urinary ...

Basilea Pharmaceutica International Ltd, Allschwil: Basilea receives further USD 6 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, February 25, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to ...